Health
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease – nejm.org
Original Article from The New England Journal of Medicine — Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
From the DanaFarber/Boston Childrens Cancer and Blood Disorders Center, Harvard Medical School (E.B.E., L.E.L., A.B., C.B., M.F.C., B.M., K.B., S.-Y.P., W.B.L., C.D., M.M.H., D.A.W.), the Harvard Stem Cell Institute, Harvard Medical School (A.B., C.B.), the Gene Therapy Program, DanaFarber/Boston Childrens Cancer and Blood Disorders Center (A.B., M.F.C., B.M., E.M., A.F., S.-Y.P., C.D., D.A.W.), the Division of Hematology, Brigham and Womens Hospital, Harvard Medical School (M. Achebe), the Connell…
-
Noosa News24 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
Noosa News23 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years
-
Noosa News19 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan
-
General24 hours agoIranian supreme leader makes first public appearance since war with Israel